Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiology
Study shows differences in cardiovascular risk among cox-2 inhibitors
December 12th, 2004
Research published in a recent issue of Atherosclerosis showed cox-2 inhibitor Vioxx caused biochemical changes that contribute to the development of heart disease, while Celebrex, another cox-2 inhibitor, did not. According to the announcement, this research presents a biological explanation for reported differences in cardiovascular safety observed with cox-2s. Over the course of a 2-year investigation, researchers found important differences in the way each cox-2 inhibitor acts on a key process linked to cardiovascular disease. Vioxx made certain lipid components of the blood, particularly low-density lipoprotein (LDL), more susceptible to...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
